salirasib   Click here for help

GtoPdb Ligand ID: 6281

Synonyms: farnesylthiosalicylic acid | S-farnesylthiosalicylic acid
Compound class: Synthetic organic
Comment: Salirasib (trans-farnesylthiosalicylic acid) is an investigational small molecule which indirectly inhibits RAS protein activity. It is a salicylic acid derivative with potential antineoplastic activity.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

salirasib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 62.6
Molecular weight 358.2
XLogP 6.96
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC(=CCSc1ccccc1C(=O)O)CCC=C(CCC=C(C)C)C
Isomeric SMILES C/C(=C\CSc1ccccc1C(=O)O)/CC/C=C(/CCC=C(C)C)\C
InChI InChI=1S/C22H30O2S/c1-17(2)9-7-10-18(3)11-8-12-19(4)15-16-25-21-14-6-5-13-20(21)22(23)24/h5-6,9,11,13-15H,7-8,10,12,16H2,1-4H3,(H,23,24)/b18-11+,19-15+
InChI Key WUILNKCFCLNXOK-CFBAGHHKSA-N
References
1. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. (2005)
Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death.
Cancer Res, 65 (3): 999-1006. [PMID:15705901]
2. Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, Stärkel P. (2010)
Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Mol Cancer, 9: 256. [PMID:20860815]
3. Haklai R, Weisz MG, Elad G, Paz A, Marciano D, Egozi Y, Ben-Baruch G, Kloog Y. (1998)
Dislodgment and accelerated degradation of Ras.
Biochemistry, 37 (5): 1306-14. [PMID:9477957]
4. Maher M, Ao H, Banke T, Nasser N, Wu NT, Breitenbucher JG, Chaplan SR, Wickenden AD. (2008)
Activation of TRPA1 by farnesyl thiosalicylic acid.
Mol Pharmacol, 73 (4): 1225-34. [PMID:18171730]
5. Riely GJ, Johnson ML, Medina C, Rizvi NA, Miller VA, Kris MG, Pietanza MC, Azzoli CG, Krug LM, Pao W et al.. (2011)
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
J Thorac Oncol, 6 (8): 1435-7. [PMID:21847063]
6. Rotblat B, Ehrlich M, Haklai R, Kloog Y. (2008)
The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Meth Enzymol, 439: 467-89. [PMID:18374183]